Does the media prefer PCVX or STOK?

In the previous week, Stoke Therapeutics had 11 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Stoke Therapeutics' score of 0.28 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer APGE or STOK?

In the previous week, Stoke Therapeutics had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Stoke Therapeutics' score of 0.28 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMVT or STOK?

In the previous week, Stoke Therapeutics had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Stoke Therapeutics and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Stoke Therapeutics' score of 0.28 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IBRX or STOK?

In the previous week, Stoke Therapeutics had 12 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Stoke Therapeutics and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.13 beat Stoke Therapeutics' score of 0.28 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RYTM or STOK?

In the previous week, Stoke Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Stoke Therapeutics and 10 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.56 beat Stoke Therapeutics' score of 0.28 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Stoke Therapeutics (STOK) Competitors

$32.29 +0.89 (+2.83%)

As of 08/21/2026 04:00 PM Eastern

Compare

STOK vs. PCVX, APGE, IMVT, IBRX, and RYTM

Should you buy Stoke Therapeutics stock or one of its competitors? Stoke Therapeutics's main competitors and comparable companies include Vaxcyte (PCVX), Apogee Therapeutics (APGE), Immunovant (IMVT), ImmunityBio (IBRX), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Stoke Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Stoke Therapeutics had 11 more articles in the media than Vaxcyte. MarketBeat recorded 14 mentions for Stoke Therapeutics and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.07 beat Stoke Therapeutics' score of 0.28 indicating that Vaxcyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vaxcyte has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Vaxcyte's return on equity of -37.56% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-37.56%	-33.62%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

96.8% of Vaxcyte shares are held by institutional investors. 3.3% of Vaxcyte shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Stoke Therapeutics has higher revenue and earnings than Vaxcyte. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$7.63	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

Vaxcyte has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Vaxcyte currently has a consensus target price of $86.00, suggesting a potential upside of 37.34%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 37.04%. Given Vaxcyte's higher possible upside, research analysts plainly believe Vaxcyte is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Vaxcyte beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Stoke Therapeutics had 9 more articles in the media than Apogee Therapeutics. MarketBeat recorded 14 mentions for Stoke Therapeutics and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Stoke Therapeutics' score of 0.28 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.0% of Apogee Therapeutics shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Apogee Therapeutics currently has a consensus price target of $124.43, suggesting a potential downside of 7.66%. Stoke Therapeutics has a consensus price target of $44.25, suggesting a potential upside of 37.04%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Stoke Therapeutics is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Apogee Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Apogee Therapeutics' return on equity of -29.88% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Apogee Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Stoke Therapeutics has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

Summary

Stoke Therapeutics beats Apogee Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Stoke Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

Immunovant has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Immunovant presently has a consensus target price of $44.00, suggesting a potential downside of 0.83%. Stoke Therapeutics has a consensus target price of $44.25, suggesting a potential upside of 37.04%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Stoke Therapeutics had 6 more articles in the media than Immunovant. MarketBeat recorded 14 mentions for Stoke Therapeutics and 8 mentions for Immunovant. Immunovant's average media sentiment score of 0.97 beat Stoke Therapeutics' score of 0.28 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Stoke Therapeutics beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

ImmunityBio has a net margin of -598.55% compared to Stoke Therapeutics' net margin of -753.60%. ImmunityBio's return on equity of 0.00% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-598.55%	N/A	-51.65%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Stoke Therapeutics has higher revenue and earnings than ImmunityBio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	72.88	-$351.40M	-$0.97	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

ImmunityBio has a beta of 0.03, meaning that its stock price is 97% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

ImmunityBio currently has a consensus price target of $14.20, indicating a potential upside of 82.28%. Stoke Therapeutics has a consensus price target of $44.25, indicating a potential upside of 37.04%. Given ImmunityBio's higher probable upside, equities analysts plainly believe ImmunityBio is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

8.6% of ImmunityBio shares are owned by institutional investors. 66.1% of ImmunityBio shares are owned by insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Stoke Therapeutics had 12 more articles in the media than ImmunityBio. MarketBeat recorded 14 mentions for Stoke Therapeutics and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.13 beat Stoke Therapeutics' score of 0.28 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

ImmunityBio beats Stoke Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Stoke Therapeutics (NASDAQ:STOK) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Rhythm Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus price target of $142.44, indicating a potential upside of 29.49%. Stoke Therapeutics has a consensus price target of $44.25, indicating a potential upside of 37.04%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Stoke Therapeutics has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.73	-$196.54M	-$3.11	N/A
Stoke Therapeutics	$184.42M	11.30	-$6.89M	-$3.34	N/A

In the previous week, Stoke Therapeutics had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 14 mentions for Stoke Therapeutics and 10 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.56 beat Stoke Therapeutics' score of 0.28 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rhythm Pharmaceuticals beats Stoke Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.08B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-9.67	11.62	272.60	24.24
Price / Sales	11.30	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	6.02	16.80	13.05	6.20
Net Income	-$6.89M	-$12.50M	$3.47B	$348.59M
7 Day Performance	3.26%	3.29%	2.09%	0.08%
1 Month Performance	8.90%	8.23%	6.64%	3.88%
1 Year Performance	65.08%	55.05%	25.02%	16.98%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	2.4461 of 5 stars	$32.29 +2.8%	$44.25 +37.0%	+65.1%	$2.08B	$184.42M	N/A	100	Analyst Forecast Insider Trade
PCVX Vaxcyte	2.2586 of 5 stars	$58.29 +0.4%	$86.00 +47.5%	+93.9%	$8.39B	N/A	N/A	160	Positive News
APGE Apogee Therapeutics	1.3679 of 5 stars	$134.65 -0.1%	$121.25 -9.9%	+252.1%	$8.34B	N/A	N/A	91	Positive News
IMVT Immunovant	1.4326 of 5 stars	$39.89 -0.2%	$44.00 +10.3%	+191.1%	$8.25B	N/A	N/A	120
IBRX ImmunityBio	2.6599 of 5 stars	$7.49 -2.0%	$14.20 +89.6%	+237.2%	$8.10B	$113.29M	N/A	590	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. PCVX, APGE, IMVT, IBRX, and RYTM

How does Stoke Therapeutics compare to Vaxcyte?

Summary

How does Stoke Therapeutics compare to Apogee Therapeutics?

Summary

How does Stoke Therapeutics compare to Immunovant?

Summary

How does Stoke Therapeutics compare to ImmunityBio?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. PCVX, APGE, IMVT, IBRX, and RYTM

How does Stoke Therapeutics compare to Vaxcyte?

Does the media prefer PCVX or STOK?

Is PCVX or STOK more profitable?

Do insiders & institutionals have more ownership in PCVX or STOK?

Which has stronger valuation & earnings, PCVX or STOK?

Which has more risk & volatility, PCVX or STOK?

Do analysts recommend PCVX or STOK?

Summary

How does Stoke Therapeutics compare to Apogee Therapeutics?

Does the media prefer APGE or STOK?

Do insiders and institutionals have more ownership in APGE or STOK?

Do analysts rate APGE or STOK?

Is APGE or STOK more profitable?

Which has more risk & volatility, APGE or STOK?

Which has stronger valuation and earnings, APGE or STOK?

Summary

How does Stoke Therapeutics compare to Immunovant?

Do institutionals & insiders have more ownership in IMVT or STOK?

Is IMVT or STOK more profitable?

Which has higher valuation & earnings, IMVT or STOK?

Which has more volatility & risk, IMVT or STOK?

Do analysts rate IMVT or STOK?

Does the media prefer IMVT or STOK?

Summary

How does Stoke Therapeutics compare to ImmunityBio?

Is IBRX or STOK more profitable?

Which has preferable earnings & valuation, IBRX or STOK?

Which has more volatility and risk, IBRX or STOK?

Do analysts rate IBRX or STOK?

Do insiders and institutionals believe in IBRX or STOK?

Does the media prefer IBRX or STOK?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Which has more risk & volatility, RYTM or STOK?

Do analysts prefer RYTM or STOK?

Is RYTM or STOK more profitable?

Which has preferable valuation and earnings, RYTM or STOK?

Does the media favor RYTM or STOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools